We report our own experience in application of isotretinoin in the treatment of 40 patients with varying severity of acne. Efficacy and safety of Aknekutan and severity of side effects were assessed. Objective. This study was aimed at investigating clinical efficacy and safety of isotretinoin (Aknekutan) in treatment of patients with various severity of acne. Material and methods. The study involved 40 patients with various severity of acne, including 26 (65%) females and 14 (35%) males aged 14 to 40 years, who received Aknekutan as monotherapy. Results. Significant positive dynamics in skin condition (reduced number of comedones, papules, pustules, nodules, scars, and dyschromia) was observed after 2 months of therapy. After 3 months of therapy, clinical remission (absence of comedones, papules, pustules, and nodules) was observed in most patients (85%), as well as significant decrease in dyschromia and scarring (65%). After 5 months of therapy, complete clinical remission was achieved in all 40 (100%) of patients. Conclusions. The results of the study showed high efficacy, safety, and tolerability of Aknekutan, which makes it possible to use it as the primary medication in treatment of severe and refractory forms of acne in various age groups of patients.